Hepatocellular carcinoma recurrence rates and patterns did not differ between patients who underwent interferon-based antiviral therapy for hepatitis C and those who received direct-acting antiviral ...
A study published in 2016 raised concerns that patients with liver cancer related to hepatitis C virus (HCV) may have a higher risk for recurrence if they are treated with direct-acting antiviral (DAA ...
Introduction: Data on the risk of hepatocellular carcinoma (HCC) recurrence in a transplanted liver following direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection are sparse and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback